Weathering the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond
暂无分享,去创建一个
E. Winer | J. Bellon | N. Lin | T. King | H. Muss | C. Block | C. Minami | R. Freedman | N. VanderWalde | M. Sedrak | T. Jolly
[1] T. Rea,et al. Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington , 2020, The New England journal of medicine.
[2] G. Onder,et al. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. , 2020, JAMA.
[3] Christl A. Donnelly,et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis , 2020, The Lancet Infectious Diseases.
[4] R. Redfield,et al. Covid-19 — Navigating the Uncharted , 2020, The New England journal of medicine.
[5] C. Tournigand,et al. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial , 2019, The Lancet.
[6] C. Caldas,et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial , 2019, The Lancet.
[7] Yuan Yuan,et al. Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer. , 2018, The Lancet. Oncology.
[8] H. Cohen,et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] E. Winer,et al. Breast cancer‐specific survival by age: Worse outcomes for the oldest patients , 2018, Cancer.
[10] O. Abdel-Rahman. Impact of timeliness of adjuvant chemotherapy and radiotherapy on the outcomes of breast cancer; a pooled analysis of three clinical trials. , 2018, Breast.
[11] M. Goetz,et al. Predicting Nodal Positivity in Women 70 Years of Age and Older with Hormone Receptor-Positive Breast Cancer to Aid Incorporation of a Society of Surgical Oncology Choosing Wisely Guideline into Clinical Practice , 2017, Annals of Surgical Oncology.
[12] H. Gómez,et al. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] E. Winer,et al. Surveillance Mammography in Older Patients With Breast Cancer—Can We Ever Stop?: A Review , 2017, JAMA oncology.
[14] L. V. van't Veer,et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. , 2016, The New England journal of medicine.
[15] L. Fan,et al. Influence of delayed initiation of adjuvant chemotherapy on breast cancer survival is subtype-dependent , 2016, Oncotarget.
[16] C. Perou,et al. Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts , 2016, Clinical Cancer Research.
[17] S. Giordano,et al. Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer. , 2016, JAMA oncology.
[18] C. Gross,et al. The evolving role of adjuvant radiotherapy for elderly women with early‐stage breast cancer , 2015, Cancer.
[19] T. Ohmura,et al. A phase I study of combination therapy with nanoparticle albumin-bound paclitaxel and cyclophosphamide in patients with metastatic or recurrent breast cancer , 2015, International Journal of Clinical Oncology.
[20] D. Cameron,et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. , 2015, The Lancet. Oncology.
[21] N. Bhavsar,et al. The use of adjuvant radiotherapy in elderly patients with early‐stage breast cancer: Changes in practice patterns after publication of Cancer and Leukemia Group B 9343 , 2015, Cancer.
[22] Barbara L. Smith,et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] P. Boracchi,et al. Axillary Dissection Versus No Axillary Dissection in Older Patients With T1N0 Breast Cancer: 15-Year Results of a Randomized Controlled Trial , 2012, Annals of surgery.
[24] Benjamin D. Smith,et al. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. , 2011, International journal of radiation oncology, biology, physics.
[25] N. Taira,et al. Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)]. , 2011, Japanese journal of clinical oncology.
[26] D. Lake,et al. Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer. , 2010, Clinical breast cancer.
[27] J. Sakamoto,et al. Phase I study of combination therapy with weekly paclitaxel and cyclophosphamide for advanced or recurrent breast cancer , 2010, Cancer Chemotherapy and Pharmacology.
[28] P. Sismondi,et al. Conservative surgery with and without radiotherapy in elderly patients with early-stage breast cancer: a prospective randomised multicentre trial. , 2009, Breast.
[29] J R Yarnold,et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial , 2008, The Lancet.
[30] M. Reed,et al. Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane review , 2007, British Journal of Cancer.
[31] R. Pötter,et al. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. , 2005, International journal of radiation oncology, biology, physics.
[32] Melania Pintilie,et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. , 2004, The New England journal of medicine.
[33] Barbara L. Smith,et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. , 2004, The New England journal of medicine.
[34] M. Baum,et al. Late follow‐up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer , 2004, The British journal of surgery.
[35] Barbara L. Smith,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] S. Milani,et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] I. Fentiman,et al. Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. , 2003, European journal of cancer.
[38] I. Olivotto,et al. Age-related variations in the use of axillary dissection: a survival analysis of 8038 women with T1-ST2 breast cancer. , 2002, International journal of radiation oncology, biology, physics.
[39] F. Cavalli,et al. Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] R. Coombes,et al. Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. , 1994, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[41] M. Beckmann,et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. , 2018, The Lancet. Oncology.
[42] A. Jemal,et al. Patterns of axillary evaluation in older patients with breast cancer and associations with adjuvant therapy receipt , 2017, Breast Cancer Research and Treatment.
[43] C. Lawton. Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer , 2011 .
[44] Robert B Livingston,et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. , 2010, The Lancet. Oncology.
[45] J. Forbes,et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] F. Cavalli,et al. Dose-finding study of paclitaxel and cyclophosphamide in women with advanced breast cancer. , 1997, Seminars in oncology.